CRLF3 protein and antibodies were collectively increased in breast cancer (principally invasive carcinoma), with CRLF3 antibodies significantly elevated in early-stage breast cancer compared to controls, in HER2+ versus luminal A forms, and in both of these versus triple-negative (TN) forms [70]. Here, ERBB2 is linked to breast carcinoma.